Last reviewed · How we verify
PANVAC™-VF
PANVAC-VF is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing ras and CEA tumor-associated antigens.
PANVAC-VF is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing ras and CEA tumor-associated antigens. Used for Metastatic colorectal cancer, Pancreatic cancer.
At a glance
| Generic name | PANVAC™-VF |
|---|---|
| Sponsor | Therion Biologics Corporation |
| Drug class | Therapeutic cancer vaccine |
| Target | ras and CEA (carcinoembryonic antigen) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PANVAC-VF combines a vaccinia virus vector expressing ras and CEA antigens with a fowlpox virus booster to generate cellular and humoral immune responses against tumor cells. The vaccine is designed to activate T cells and other immune effectors to target cancers that express these common tumor-associated antigens, particularly in colorectal and other gastrointestinal malignancies.
Approved indications
- Metastatic colorectal cancer
- Pancreatic cancer
Common side effects
- Injection site reactions
- Fever
- Fatigue
- Myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PANVAC™-VF CI brief — competitive landscape report
- PANVAC™-VF updates RSS · CI watch RSS
- Therion Biologics Corporation portfolio CI